(Q41579452)

4 October 2017

1 reference

title

Androgens and prostate cancer: biology, pathology and hormonal therapy (English)

1 reference

4 October 2017

2

1 reference

4 October 2017

Galbraith SM

1

1 reference

4 October 2017

publication date

1 April 1997

1 reference

European Journal of Cancer

4 October 2017

published in

1 reference

4 October 2017

volume

33

1 reference

4 October 2017

issue

4

1 reference

4 October 2017

page(s)

545-554

1 reference

The endocrinology and developmental biology of the prostate

4 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Metabolic action of prolactin in regressing prostate: independent of androgen action

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Growth hormone and prostatic tumours: localization using a monoclonal human growth hormone antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Localization of epidermal growth factor receptors in the human prostate by biochemical and immunocytochemical methods

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Steroid-growth factor interaction in human prostate cancer. 1. Short-term effects of transforming growth factors on growth of human prostate cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Neuroendocrine differentiation in human prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

The human androgen receptor: domain structure, genomic organization and regulation of expression.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Randomised controlled study of orchidectomy vs long-acting D-Trp-6-LHRH microcapsules in advanced prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Carcinoma of the prostate. Hormonal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Hormonal Effects of Cessation of Estrogen Treatment for Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Characterization and measurement of the androgen receptor in human benign prostatic hyperplasia and prostatic hyperplasia and prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Leuprolide versus diethylstilbestrol for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Comparison of Diethylstilbestrol, Cyproterone Acetate and Medroxyprogesterone Acetate in the Treatment of Advanced Prostatic Cancer: Final Analysis of a Randomized Phase III Trial of the European Organization for Research on Treatment of Cancer Urolo

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Experience with Flutamide in Previously Untreated Patients With Advanced Prostatic Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Site of Action of Low Dose Ketoconazole on Androgen Biosynthesis in Men*

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Ketoconazole therapy for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Aminoglutethimide: medical adrenalectomy in the management of carcinoma of the prostate. A review after 6 years

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

1 reference

7 January 2021

Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Androgen receptor alterations in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Androgen receptor gene mutations in human prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Two prostate carcinoma cell lines demonstrate abnormalities in tumor suppressor genes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Low Androgen Levels Induce the Development of Androgen-Hypersensitive Cell Clones in Shionogi Mouse Mammary Carcinoma Cells in Culture

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Zoladex and flutamide versus orchiectomy in the treatment of advanced prostatic cancer. A combined analysis of two European studies, EORTC 30853 and DAPROCA 86

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

The role of neoadjuvant hormonal manipulation in localized prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2896%2900444-3

7 January 2021

10.1016/S0959-8049(96)00444-3

Identifiers

DOI

1 reference

4 October 2017

1 reference